Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2014 1
2015 1
2016 3
2017 4
2018 3
2020 4
2021 7
2022 11
2023 12
2024 16
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: Clinical Trial, Humans. Clear all
Page 1
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.
Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, McGregor BA, Harvey K, Tai M, Kollefrath A, Thomas BJ, Sorta D, Kaelen M, Kelmendi B, Gooley TA. Back AL, et al. JAMA Netw Open. 2024 Dec 2;7(12):e2449026. doi: 10.1001/jamanetworkopen.2024.49026. JAMA Netw Open. 2024. PMID: 39636638 Free PMC article. Clinical Trial.
IMPORTANCE: The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during the COVID-19 pandemic includes burnout, depression, and posttraumatic stress disorder (PTSD). OBJECTIVE: To investigate whether …
IMPORTANCE: The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during th …
Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial.
Swanson LR, Jungers S, Varghese R, Cullen KR, Evans MD, Nielson JL, Schallmo MP. Swanson LR, et al. J Vis. 2024 Nov 4;24(12):5. doi: 10.1167/jov.24.12.5. J Vis. 2024. PMID: 39499526 Free PMC article. Clinical Trial.
We asked whether surround suppression is altered under peak effects of psilocybin. Using a contrast-matching task with different center-surround stimulus configurations, we measured surround suppression after 25 mg of psilocybin compared with placebo (100 mg niacin) …
We asked whether surround suppression is altered under peak effects of psilocybin. Using a contrast-matching task with different cent …
The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.
Marwood L, Croal M, Mistry S, Simmons H, Tsai J, Young MB, Goodwin GM. Marwood L, et al. J Psychiatr Res. 2024 Dec;180:198-203. doi: 10.1016/j.jpsychires.2024.10.009. Epub 2024 Oct 11. J Psychiatr Res. 2024. PMID: 39427449 Free article. Clinical Trial.
Data from 233 participants with treatment-resistant depression (TRD) who received 25 mg, 10 mg, or 1 mg of investigational drug COMP360 psilocybin (a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by the sponsor, Compass Pathfin …
Data from 233 participants with treatment-resistant depression (TRD) who received 25 mg, 10 mg, or 1 mg of investigational drug COMP3 …
Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
Ellis S, Bostian C, Feng W, Fischer E, Schwartz G, Eisen K, Lean M, Conlan E, Ostacher M, Aaronson S, Suppes T. Ellis S, et al. J Affect Disord. 2025 Jan 15;369:381-389. doi: 10.1016/j.jad.2024.09.133. Epub 2024 Sep 27. J Affect Disord. 2025. PMID: 39343309 Clinical Trial.
BACKGROUND: The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability. This is the first study to evaluate the efficacy and safety of psilocybin in Veterans with severe treatmen …
BACKGROUND: The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates …
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
Calder AE, Rausch B, Liechti ME, Holze F, Hasler G. Calder AE, et al. J Psychopharmacol. 2024 Oct;38(10):873-886. doi: 10.1177/02698811241278873. Epub 2024 Sep 20. J Psychopharmacol. 2024. PMID: 39302087 Free PMC article. Clinical Trial.
All participants received varying doses of psilocybin and LSD. Subjective effects were assessed on an hourly basis during the acute drug effects, and the Mystical Experience Questionnaire (MEQ) was completed retrospectively. For patients, depressive symptoms were as …
All participants received varying doses of psilocybin and LSD. Subjective effects were assessed on an hourly basis during the acute d …
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P; BEDROC study investigators. Glue P, et al. Nat Med. 2024 Jul;30(7):2004-2009. doi: 10.1038/s41591-024-03063-x. Epub 2024 Jun 24. Nat Med. 2024. PMID: 38914860 Free PMC article. Clinical Trial.
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administratio …
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerabi …
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.
Sloshower J, Zeifman RJ, Guss J, Krause R, Safi-Aghdam H, Pathania S, Pittman B, D'Souza DC. Sloshower J, et al. Sci Rep. 2024 Apr 17;14(1):8833. doi: 10.1038/s41598-024-58318-x. Sci Rep. 2024. PMID: 38632313 Free PMC article. Clinical Trial.
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). ...Psychological flexibility, several facets of mindfulness, a …
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsy …
Psychedelics and the 'inner healer': Myth or mechanism?
Peill J, Marguilho M, Erritzoe D, Barba T, Greenway KT, Rosas F, Timmermann C, Carhart-Harris R. Peill J, et al. J Psychopharmacol. 2024 May;38(5):417-424. doi: 10.1177/02698811241239206. Epub 2024 Apr 12. J Psychopharmacol. 2024. PMID: 38605658 Free PMC article. Clinical Trial.
METHODS: The item was issued to 59 patients after a single high (25 mg, n = 30) or 'placebo' (1 mg, n = 29) dose of psilocybin in a double-blind randomised controlled trial of psilocybin for depression. RESULTS: Inner healer scores were higher after the high …
METHODS: The item was issued to 59 patients after a single high (25 mg, n = 30) or 'placebo' (1 mg, n = 29) dose of psilocybin in a d …
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.
Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R. Erritzoe D, et al. J Psychopharmacol. 2024 May;38(5):458-470. doi: 10.1177/02698811241237870. Epub 2024 Mar 22. J Psychopharmacol. 2024. PMID: 38520045 Free PMC article. Clinical Trial.
BACKGROUND: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norep …
BACKGROUND: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. How …
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.
Levin AW, Lancelotta R, Sepeda ND, Gukasyan N, Nayak S, Wagener TL, Barrett FS, Griffiths RR, Davis AK. Levin AW, et al. PLoS One. 2024 Mar 14;19(3):e0300501. doi: 10.1371/journal.pone.0300501. eCollection 2024. PLoS One. 2024. PMID: 38483940 Free PMC article. Clinical Trial.
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression …
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PA …
54 results

Searches related to "psilocybin depression"